What does published research say about BPC-157 and the gut?

Published August 22, 2026 · Artemis Labs

BPC-157 and the digestive tract — answer capsule: BPC-157 is a 15-amino-acid peptide whose sequence is a partial copy of a protein found in human gastric juice, the fluid the stomach makes to break down food. That origin is why the earliest research on it looked at the digestive tract rather than at tendons or skin. Published work reports the peptide stays intact in human gastric juice for more than 24 hours, unusual for a small peptide with no chemical modifications. The gut studies themselves are rat work: duodenal injury with a blocked major vein, and a punctured stomach wall. No published Phase II or Phase III human efficacy trial exists for any use, so every gut finding here is an animal or tissue observation.

Key findings

• The sequence is not invented. BPC-157 is a partial sequence of a protein found in human gastric juice, and it is catalogued as PubChem CID 9941957, CAS 137525-51-0, molecular weight 1,419.54 g/mol.
• Published studies report the peptide remaining intact in human gastric juice for more than 24 hours. The credited structural feature is a triple-proline motif — three proline units in a row at positions 3 to 5 — associated with resistance to being broken apart by enzymes.
• Sikiric 2018 (DOI: 10.2174/1381612824666180608101119) gathers the gastrointestinal animal work under the idea of cytoprotection — helping the cells lining an organ survive an injury — and ties it to blood-vessel recruitment.
• Two rat models carry most of the specific gut evidence: Amam 2018 (DOI: 10.3748/wjg.v24.i47.5366), a blocked-major-vein plus duodenal-lesion model, and Kalogjera 2023 (DOI: 10.3748/wjg.v29.i27.4289), a stomach-perforation model.

Where did BPC-157 come from?

A peptide is a short chain of amino acids, the building blocks that link together to form proteins. BPC-157 is 15 of them, in the order Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, shortened to GEPPPGKPADDAGLV. Formula C₆₂H₉₈N₁₆O₂₂, molecular weight 1,419.54 g/mol.

Nobody drew that sequence up from nothing. It is a partial sequence of a protein found in human gastric juice — the acidic fluid the stomach produces to break food down. Researchers took a fragment of something the body already keeps in one of the harshest environments it has and studied the fragment on its own.

That history explains its names in the literature: Body Protection Compound 157, PL 14736, and stable gastric pentadecapeptide BPC 157. “Pentadecapeptide” is the technical way of saying a peptide with 15 amino acids; “gastric” points back to the stomach.

Artemis Labs supplies the BPC-157 research peptide as a lyophilized powder with a lot-specific certificate of analysis, for laboratory research use. Our guide to recovery and tissue repair peptides maps how it sits alongside the rest of the category.

Why does BPC-157 stay in one piece in the stomach?

Most small peptides do not last long in the digestive tract. The stomach is full of enzymes — proteins whose job is to cut other proteins into pieces — and a short unprotected chain of amino acids is an easy target. Peptide drugs usually have to be modified chemically to slow that breakdown.

BPC-157 carries no such modifications, and published studies still report it intact in human gastric juice past 24 hours. The feature credited for that is the triple-proline motif: three proline amino acids in a row at positions 3, 4, and 5. Runs of proline are associated with resistance to enzymatic cutting, and this one sits early in the chain.

Keep the scope of that result straight: it measures how long the molecule survives in a fluid. It says nothing about what the compound does in a person.

What have the gut studies actually tested?

Sikiric 2018 is the anchor reference. It is a synthesis — a paper that gathers many earlier experiments and argues a common thread through them — built around cytoprotection, the idea that a compound can help cells in an organ lining survive damage. It connects gastrointestinal healing observations in animal models to vascular recruitment, meaning the body rerouting blood through nearby vessels when a normal route is compromised.

Amam 2018 is a specific rat experiment rather than a review. The researchers created two problems at once: lesions (sores) in the duodenum, the first section of small intestine just past the stomach, and a deliberately blocked major vein. That pairing is how they tested whether the effects tracked with blood flow rather than with the gut lining alone.

Kalogjera 2023 used another rat model — a perforated stomach, meaning a hole made in the stomach wall, studied as part of an occlusion syndrome where circulation is obstructed. Same line of work: a serious structural injury to the digestive tract combined with a circulation problem, in rats. None of these studies involved people with a gut condition.

How do researchers think it acts on gut tissue?

The most-tested idea is the nitric oxide system. Nitric oxide is a gas the body makes as a signal, and one of its main jobs is telling blood vessels to widen. Amam 2018 tested this the standard pharmacological way, running BPC-157 alongside L-NAME, which blocks the body’s production of nitric oxide, and L-arginine, the raw material the body uses to make it. If an effect shrinks with the blocker and returns with the raw material, that points to the effect running through that system.

The second thread is blood-vessel growth. Preclinical studies report BPC-157 raising levels of VEGF receptor 2 — a docking point on cells for a signal that drives new blood vessel formation — with Akt and endothelial nitric oxide synthase activated further down the same chain. That axis is the canonical explanation for new-vessel observations at injury sites in animals, and it recurs in other research areas, including the nervous system animal models.

None of this is settled. BPC-157 has a multi-pathway profile with no single defined receptor, no canonical binding assay separating a positive result from a null one, and no agreed biomarker of activity. Effect sizes across the published corpus vary substantially with model, dose, route, and species.

What the research does not show

No published Phase II or Phase III human efficacy trial exists for BPC-157, for gut conditions or for anything else. Pilot human safety work is referenced in review papers such as Mendias 2026 (PMID 41966639), but safety pilots do not test whether a compound works. Every efficacy statement anywhere about this compound is extrapolated from animals or tissue.

Rat digestive tracts are not human digestive tracts, and a surgically created lesion is not the same problem as a chronic condition in a person. Our page on what the safety literature does and does not cover works through that gap.

The regulatory picture is unsettled and should be described that way. BPC-157 is not an FDA-approved drug for any use. It was given interim Category 2 status for 503A compounding in September 2023, then removed from that list on September 27, 2024 after the nominator withdrew, and it is now under Pharmacy Compounding Advisory Committee review. An FDA advisory committee vote in July 2026 was non-binding. It is also on the WADA Prohibited List under Section S2, prohibited at all times, so a tested athlete faces an anti-doping violation regardless of where the material came from.

One caveat belongs here only because BPC-157 appears in multi-peptide blends. Sun 2025 (PMID 41278163) reported that mast-cell-released thymosin beta-4 impaired the intestinal epithelial barrier — the lining that controls what crosses out of the gut — in irritable bowel syndrome models, via IL22RA1/JAK1/STAT3. That finding is about thymosin beta-4, the parent of TB-500. It is not a finding about BPC-157 and should not be read as one. It appears here only because some blends pair the two compounds, and no study shows those blends outperform their components.

Frequently asked questions

Does the human body make BPC-157?

Not as such. The sequence is a partial sequence of a protein found in human gastric juice, so the fragment corresponds to something present in the body. The compound as studied and as sold for research is synthesized.

Has BPC-157 been tested in people for digestive conditions?

Not in a published Phase II or Phase III efficacy trial. The gut evidence is rat models and reviews of rat models; human work in the literature is limited to pilot safety references.

Why is it called “stable gastric pentadecapeptide”?

Two facts, not a claim. “Pentadecapeptide” means 15 amino acids. “Stable gastric” points to the published observation that the molecule stays intact in human gastric juice beyond 24 hours.

What does the research say about blends containing BPC-157?

No published study shows a blend performing better than its individual components. Blends are described in terms of mechanism complementarity — a hypothesis about overlapping pathways, not a demonstrated result.

References

1. Sikiric P, et al. Cytoprotection synthesis: vascular recruitment and gastrointestinal-tract healing (2018). DOI: 10.2174/1381612824666180608101119
2. Amam, et al. Major venous occlusion and duodenal lesion rat model; nitric-oxide pathway pharmacology (2018). DOI: 10.3748/wjg.v24.i47.5366
3. Kalogjera L, et al. Stomach-perforation and occlusion-syndrome rat model (2023). DOI: 10.3748/wjg.v29.i27.4289
4. Mendias CL, Awan TM. Sports Med. 2026. PMID 41966639
5. Sun, et al. Mast-cell-released thymosin beta-4 and intestinal epithelial barrier in IBS models (2025). PMID 41278163

Methodology: this page draws on the Artemis Labs BPC-157 research record — peer-reviewed animal, tissue, and review literature carrying a live PMID or DOI — plus compound identity data from PubChem CID 9941957 and published FDA and WADA status. Citations last verified August 22, 2026.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.